FindTrial
Sign In

GVAX Pancreas Vaccine

BIOLOGICAL7 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Aduro Biotech, Inc.

Conditions

2nd-line, 3rd-line and Greater Metastatic Pancreatic CancerMetastatic Pancreatic AdenocarcinomaPancreatic Cancer

Phase 2

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer
CompletedNCT00389610
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer
Start: 2006-09-11End: 2022-12-10Updated: 2023-10-26
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
Active, not recruitingNCT01088789
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer
Start: 2010-04-20End: 2026-08-31Updated: 2025-08-26
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
CompletedNCT01595321
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer
Start: 2012-10-29End: 2023-10-18Updated: 2024-08-14
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
CompletedNCT02004262
Aduro Biotech, Inc.2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Start: 2014-02-05End: 2016-08-23Updated: 2018-06-04
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
CompletedNCT03006302
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Pancreatic Adenocarcinoma
Start: 2018-01-31End: 2024-08-05Updated: 2024-10-08
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
CompletedNCT03161379
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer
Start: 2018-02-02End: 2024-02-28Updated: 2025-02-03
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
CompletedNCT03190265
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer
Start: 2017-12-14End: 2023-08-23Updated: 2024-08-07

Related Papers

Data from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC
2026-03-04
A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDAC.
2026-01-12
Abstract PR-08: Reprogramming and selective recruitment of distinct neutrophil subpopulations restrain cancer metastasis
Cancer Research2024-09-15
Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC).
Journal of Clinical Oncology2023-06-016 citations
Abstract CT164: A Phase II clinical trial of GVAX pancreas vaccine (with Cyclophosphamide) in combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC)
Cancer Research2019-07-011 citations
Abstract CT164: A Phase II clinical trial of GVAX pancreas vaccine (with Cyclophosphamide) in combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC)
Clinical Trials2019-07-01
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
2019-05-24199 citations
Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).
Journal of Clinical Oncology2017-02-0145 citations
A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).
Journal of Clinical Oncology2015-01-202 citations
A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).
Journal of Clinical Oncology2014-05-20
A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone...
Columbia Academic Commons (Columbia University)2014-01-01